Evarucabgene Autoleucel clinical trials
How each study uses Evarucabgene Autoleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Evarucabgene Autoleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2024 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Nexcella Inc. (2) · Polina Stepensky (2) · Hadassah Medical Organization (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test Evarucabgene Autoleucel.
- Nov 2026Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune DiseasesPhase 1 · Polina Stepensky
- Dec 2026Study of NXC-201 CAR-T in Patients With Light Chain (AL) AmyloidosisPhase 1/2 · Nexcella Inc.
- Jan 2027NXC-201 (Formerly HBI0101) Multiple MyelomaPhase 1 · Hadassah Medical Organization
Studies
Open first, then newest update. How each study uses Evarucabgene Autoleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain AmyloidosisRecruitingPhase 2Polina StepenskyNCT06971380Written as HBI0101 CART
- A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL AmyloidosisNot yet recruitingPhase 3Nexcella Inc.NCT07709715Written as NXC-201
- Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune DiseasesRecruitingPhase 1Polina StepenskyNCT07085676Written as HBI0101 CART
- NXC-201 (Formerly HBI0101) Multiple MyelomaActive, not recruitingPhase 1Hadassah Medical OrganizationNCT04720313Written as NXC-201 (formerly HBI0101)
- Study of NXC-201 CAR-T in Patients With Light Chain (AL) AmyloidosisActive, not recruitingPhase 1/2Nexcella Inc.NCT06097832Written as NXC-201 CAR-T